Talk Presenting Companies (Theatre B) track
Antibodies: Toursynbio
Tue, Nov 10, 2026 · 9:15–9:30 AM CET Koelnmesse
About this session
To date, Toursynbio has advanced 16 antibody programs through PCC-stage validation within six months and generated leading experimental results against highly challenging targets, including GPCRs and intrinsically disordered protein regions. As one of the few biotechnology companies in China to fully integrate AI computing with automated laboratory infrastructure, Toursynbio is building an AI-powered biologics foundry that accelerates therapeutic innovation and establishes a new paradigm for biopharmaceutical R&D.
Speaker
-
Founder and CEO · Toursynbio
Speaker